Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It initially appeared to have an acceptable safety profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity noted in clinical trials. It was developed by Global Blood Therapeutics, a subsidiary of Pfizer.
via Wikipedia infobox
{{Infobox drug | image = File:Voxelotor skeletal.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Oxbryta | Drugs.com = | MedlinePlus = a620011 | DailyMedID = Voxelotor | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATC_prefix = B06 | ATC_suffix = AX03 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).